Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Head & Neck cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
KY1044-CT01Safety and efficacy of KY1044 and atezolizumab in advanced cancer : A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies | |
|---|---|
| Local Project Reference: | 113776 |
| Principal Investigator: | Dr. Rebecca Roylance |
| Drug Class/ Treatment: | KY1044 (Anti-ICOS Human Monoclonal IgG1 Antibody) + Atezolizumab (Anti-PD-L1 IgG1 Monoclonal Antibody) KY1044 Single Agent and in Combination with Atezolizumab |
| Patient Population: | Head and Neck Squamous Cell Carcinoma (HNSCC) Cohort |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
POPPYA phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck | |
|---|---|
| Local Project Reference: | 17/0396 |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | Pembrolizumab (PD-1 Inhibitor) |
| Patient Population: | Recurrent or Metastatic Head & Neck Squamos Cell Carcinoma (HNSCC) |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
KO-TIP-007 (The AIM-HN and SEQ-HN Study)The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN). | |
|---|---|
| Local Project Reference: | 113051 |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | Tipifarnib (Farnesyltransferase Inhibitors) |
| Patient Population: | Head & Neck Squamos Cell Carcinoma (HNSCC) with HRAS Mutation |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
